Ductal access for prevention and therapy of mammary tumors

Cancer Research

Volumn 66, Issue 2, 2006, Pages 638-645

  Murata, Satoshi ^a,b   Kominsky, Scott L ^a   Vali, Mustafa ^a   Zhang, Zhe ^a   Garrett Mayer, Elizabeth ^a   Korz, Dorian ^a   Huso, David ^a   Baker, Sharyn D ^a   Barber, James ^a   Jaffee, Elizabeth ^a   Reilly, R Todd ^a   Sukumar, Saraswati ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; ANTINEOPLASTIC AGENT; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; METHYLNITROSOUREA; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST DUCT; CANCER ADJUVANT THERAPY; CANCER REGRESSION; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG BLOOD LEVEL; DRUG EFFICACY; INTRADUCTAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; TRANSGENIC MOUSE;

ANIMALS; DOXORUBICIN; DRUG ADMINISTRATION ROUTES; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, TRANSGENIC; NEOADJUVANT THERAPY; POLYETHYLENE GLYCOLS; RATS; TAMOXIFEN;

EID: 31544470043     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-4329     Document Type: Article

References (22)

1. McFarlin DR, Gould MN. Rat mammary carcinogenesis induced by in situ expression of constitutive Raf kinase activity is prevented by tethering Raf to the plasma membrane. Carcinogenesis 2003;24: 1149-53.
2. Sivaraman L, Gay J, Hilsenbeck SG, et al. Effect of selective ablation of proliferating mammary epithelial cells on MNU induced rat mammary tumorigenesis. Breast Cancer Res Treat 2002;73:75-83.
3. Okugawa H, Yamamoto D, Uemura Y, et al. Effect of perductal paclitaxel exposure on the development of MNU-induced mammary carcinoma in female S-D rats. Breast Cancer Res Treat 2005;91:29-34.
4. Thompson HJ, McGinley JN, Rothhammer K, Singh M. Rapid induction of mammary intraductal proliferations, ductal carcinoma in situ and carcinomas by the injection of sexually immature female rats with 1-methyl-1-nitrosourea. Carcinogenesis 1995;16: 2407-11.
5. Leonard GD, Swain SM. Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst 2004;96: 906-20.
6. Thompson HJ, McGinley JN, Wolfe P, Singh M, Steele VE, Kelloff GJ. Temporal sequence of mammary intraductal proliferations, ductal carcinomas in situ and adenocarcinomas induced by 1-methyl-1-nitrosourea in rats. Carcinogenesis 1998;19:2181-5.
7. Desta Z, Ward BA, Soukhova NV, Flockhart DA. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 2004;310:1062-75.
8. Osborne MP, Ruperto JF, Crowe JP, Rosen PP, Telang NT. Effect of tamoxifen on preneoplastic cell proliferation in N-nitroso-N-methylurea-induced mammary carcinogenesis. Cancer Res 1992;52:1477-80.
9. Martin G, Melito G, Rivera E, et al. Effect of tamoxifen on intraperitoneal N-nitroso-N-methylurea induced tumors. Cancer Lett 1996;100:227-34.
10. Russo J, Gusterson BA, Rogers AE, Russo IH, Wellings SR, van Zwieten MJ. Comparative study of human and rat mammary tumorigenesis. Lab Invest 1990;62:244-78.
11. Williams JC, Gusterson B, Humphreys J, et al. N-methyl-N-nitrosourea- induced rat mammary tumors. Hormone responsiveness but lack of spontaneous metastasis. J Natl Cancer Inst 1981;66:147-55.
12. Gabizon AA. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 2001;19:424-36.
13. Lasic DD. Doxorubicin in sterically stabilized liposomes. Nature 1996;380:561-2.
14. Sparano JA, Malik U, Rajdev L, Sarta C, Hopkins U, Wolff AC. Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer. J Clin Oncol 2001;19:3117-25.
15. Matsui W, Huff CA, Vala M, Barber J, Smith BD, Jones RJ. Anti-tumour activity of interferon-α in multiple myeloma: role of interleukin 6 and tumor cell differentiation. Br J Haematol 2003;121:251-8.
16. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S A 1992;89: 10578-82.
17. Cardiff RD. Validity of mouse mammary tumour models for human breast cancer: comparative pathology. Microsc Res Tech 2001;52:224-30.
18. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005;353:1784-92.
19. Going JJ, Moffat DF. Escaping from Flatland: clinical and biological aspects of human mammary duct anatomy in three dimensions. J Pathol 2004;203: 538-44.
20. Love SM, Barsky SH. Anatomy of the nipple and breast ducts revisited. Cancer 2004;101:1947-57.
21. Love SM, Barsky SH. Breast-duct endoscopy to study stages of cancerous breast disease. Lancet 1996; 348:997-9.
22. King BL, Love SM, Rochman S, Kim JA. The Fourth International Symposium on the Intraductal Approach to Breast Cancer, Santa Barbara, California, 10-13 March 2005. Breast Cancer Res 2005;7: 198-204.